Search
Filter Results
Displaying 1–10 of 258 for “adeno-associated virus”
-
Jul 29, 2020
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
Sep 7, 2023
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
The global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Aug 1, 2014
How Evolution is Leading to Gene Therapies for More Retinal Diseases
An innovative genetic-engineering approach called “directed evolution” to find optimal gene-delivery systems based on adeno-associated viruses (AAVs).
-
Funded Grants and Awards for Fiscal Year 2019 (July 1, 2018-June 30, 2019)
-
Aug 30, 2017
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
The MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
Jul 19, 2017
Twelve People Receive XLRS Gene Therapy in AGTC's Clinical Trial
AGTC’s gene therapy uses a human-engineered virus — and adeno-associated virus or AAV — to deliver normal copies of retinoschisin to the patient’s retina.
-
Dec 16, 2020
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
Aug 12, 2020
A Gene Therapy Primer for People with Inherited Retinal Diseases
Everything patients and families want to know about gene therapy…and a little bit more
-
May 9, 2022
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Editas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
-
May 6, 2022
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
The study is an important step toward a clinical trial of the approach